The role of PARP inhibitors in the treatment of gynecologic malignancies

Frontiers in Oncology

Volumn 3 OCT, Issue , 2013, Pages

  Reinbolt, Raquel E ^a   Hays, John L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Cervical cancer; Endometrial cancer; Niraparib; Olaparib; Ovarian cancer; PARP inhibitor; Rucaparib; Veliparib

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; BUPARLISIB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLOXURIDINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PACLITAXEL; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RUCAPARIB; TEMOZOLOMIDE; TOPOTECAN; VELIPARIB;

BREAST CANCER; CANCER CHEMOTHERAPY; CELL DEATH; DNA REPAIR; DRUG SENSITIVITY; ENDOMETRIUM CANCER; FALLOPIAN TUBE CANCER; GENE MUTATION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMAN; LETHALITY; NONHODGKIN LYMPHOMA; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER; UTERINE CERVIX CANCER;

EID: 84891068902     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00237     Document Type: Review

References (114)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63(1):11-30. doi:10.3322/caac.21166
2. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 434(7035):917-21. doi:10.1038/nature03445
3. Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis (1999) 20(2):199-203. doi:10.1093/carcin/20.2.199
4. Saffhill R, Ockey CH. Strand breaks arising from the repair of the 5-bromodeoxyuridine-substituted template and methyl methanesulphonate-induced lesions can explain the formation of sister chromatid exchanges. Chromosoma (1985) 92(3):218-24. doi:10.1007/BF00348697
5. Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, et al. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. Transl Res (2013) 161(3):156-64. doi:10.1016/j.trsl.2012.09.003
6. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 66(16):8109-15. doi:10.1158/0008-5472.CAN-06-0140
7. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 4(10):814-9. doi:10.1038/nrc1457
8. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 13(9):2728-37. doi:10.1158/1078-0432.CCR-06-3039
9. Stambolic V, Suzuki A, dela Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell (1998) 95(1):29-39. doi:10.1016/S0092-8674(00)81780-8
10. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1998) 95(26):15587-91. doi:10.1073/pnas.95.26.15587
11. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 1(6-7):315-22. doi:10.1002/emmm.200900041
12. Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med (2010) 2(53):53ra75. doi:10.1126/scitranslmed.3001538
13. McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, Bachoo RM, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res (2010) 70(13):5457-64. doi:10.1158/0008-5472.CAN-09-4295
14. Dianov GL, Hubscher U. Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res (2013) 41(6):3483-90. doi:10.1093/nar/gkt076
15. Odell ID, Wallace SS, Pederson DS. Rules of engagement for base excision repair in chromatin. J Cell Physiol (2013) 228(2):258-66. doi:10.1002/jcp.24134
16. Carson DA, Carrera CJ, Wasson DB, Yamanaka H. Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes. Adv Enzyme Regul (1988) 27:395-404. doi:10.1016/0065-2571(88)90028-3
17. David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci (2009) 14:1116-28. doi:10.2741/3297
18. Wang M, Wu W, Wu W, Rosidi B, Zhang L, Wang H, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res (2006) 34(21):6170-82. doi:10.1093/nar/gkl840
19. Haince JF, McDonald D, Rodrigue A, Dery U, Masson JY, Hendzel MJ, et al. PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem (2008) 283(2):1197-208. doi:10.1074/jbc.M706734200
20. Hirschhorn R. In vivo reversion to normal of inherited mutations in humans. J Med Genet (2003) 40(10):721-8. doi:10.1136/jmg.40.10.721
21. Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun (1963) 11:39-43. doi:10.1016/0006-291X(63)90024-X
22. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature (1980) 283(5747):593-6. doi:10.1038/283593a0
23. Kupper JH, Muller M, Jacobson MK, Tatsumi-Miyajima J, Coyle DL, Jacobson EL, et al. trans-dominant inhibition of poly(ADP-ribosyl)ation sensitizes cells against gamma-irradiation and N-methyl-N'-nitro-N-nitrosoguanidine but does not limit DNA replication of a polyomavirus replicon. Mol Cell Biol (1995) 15(6):3154-63.
24. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434(7035):913-7. doi:10.1038/nature03443
25. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 361(2):123-34. doi:10.1056/NEJMoa0900212
26. Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel TN, Helleday T. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol (2005) 25(16):7158-69. doi:10.1128/MCB.25.16.7158-7169.2005
27. Pennington KP, Walsh T, Lee M, Pennil C, Novetsky AP, Agnew KJ, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer (2013) 119(2):332-8. doi:10.1002/cncr.27720
28. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 72(21):5588-99. doi:10.1158/0008-5472.CAN-12-2753
29. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl) (2006) 84(1):16-28. doi:10.1007/s00109-005-0696-7
30. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 108(44):18032-7. doi:10.1073/pnas.1115052108
31. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science (1994) 265(5181):2088-90. doi:10.1126/science.8091231
32. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol (2008) 26(15):2568-81. doi:10.1200/JCO.2007.13.1748
33. Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res (1998) 4(10):2433-7.
34. Aida H, Takakuwa K, Nagata H, Tsuneki I, Takano M, Tsuji S, et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res (1998) 4(1):235-40.
35. Lu KH, Cramer DW, Muto MG, Li EY, Niloff J, Mok SC. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol (1999) 93(1):34-7. doi:10.1016/S0029-7844(98)00362-7
36. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 335(19):1413-6. doi:10.1056/NEJM199611073351901
37. Gaffney DK, Brohet RM, Lewis CM, Holden JA, Buys SS, Neuhausen SL, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol (1998) 47(2):129-36. doi:10.1016/S0167-8140(98)00023-1
38. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol (1998) 16(2):397-404.
39. Verhoog LC, Brekelmans CT, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol (1999) 17(11):3396-402.
40. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet (1998) 351(9099):316-21. doi:10.1016/S0140-6736(97)07065-7
41. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1-and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer (2007) 43(5):867-76. doi:10.1016/j.ejca.2006.12.009
42. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med (2007) 357(2):115-23. doi:10.1056/NEJMoa070608
43. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2009) 27(23):3764-71. doi:10.1200/JCO.2008.19.9067
44. Budroni M, Cesaraccio R, Coviello V, Sechi O, Pirino D, Cossu A, et al. Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia. BMC Cancer (2009) 9:62. doi:10.1186/1471-2407-9-62
45. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol (2008) 26(32):5284-93. doi:10.1200/JCO.2008.18.1107
46. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol (2008) 26(34):5530-6. doi:10.1200/JCO.2008.16.1703
47. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer (2003) 97(9):2187-95. doi:10.1002/cncr.11310
48. Cannistra SA. Cancer of the ovary. N Engl J Med (2004) 351(24):2519-29. doi:10.1056/NEJMra041842
49. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 28(15):2512-9. doi:10.1200/JCO.2009.26.9589
50. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 376(9737):245-51. doi:10.1016/S0140-6736(10)60893-8
51. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol (2012) 30(4):372-9. doi:10.1200/JCO.2011.36.9215
52. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol (2001) 19(14):3312-22.
53. Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or-resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol (2012) 30(31):3841-7. doi:10.1200/JCO.2011.38.8082
54. Konstantinopoulos PA, Cannistra SA. Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial. J Clin Oncol (2012) 30(4):347-50. doi:10.1200/JCO.2011.40.1489
55. Weberpals JI, Clark-Knowles KV, Vanderhyden BC. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol (2008) 26(19):3259-67. doi:10.1200/JCO.2007.11.3902
56. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 12(9):852-61. doi:10.1016/S1470-2045(11)70214-5
57. Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors. J Med Chem (2009) 52(22):7170-85. doi:10.1021/jm901188v
58. Sandhu SK, Wenham RM, Wilding G, McFadden M, Sun L, Toniatti C, et al. First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers (ASCO Meeting Abstracts). J Clin Oncol (2010) 28(15):3001. [Accessed 2013 Jun 16]. Available at: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3001
59. Drew Y, Ledermann JA, Jones A, Hall G, Jayson GC, Highley M, et al. Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer (ASCO Meeting Abstracts). J Clin Oncol (2011) 29(15):3104. [Accessed 2013 Jun 16]. Available at: http://meeting.ascopubs.org/cgi/content/short/29/15_suppl/3104?rss=1
60. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 366(15):1382-92. doi:10.1056/NEJMoa1105535
61. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet (2005) 366(9484):491-505. doi:10.1016/S0140-6736(05)67063-8
62. Dellinger TH, Monk BJ. Systemic therapy for recurrent endometrial cancer: a review of North American trials. Expert Rev Anticancer Ther (2009) 9(7):905-16. doi:10.1586/era.09.54
63. Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol (2007) 25(20):2983-90. doi:10.1200/JCO.2007.10.8431
64. Llaurado M, Ruiz A, Majem B, Ertekin T, Colas E, Pedrola N, et al. Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinol (2012) 358(2):244-55. doi:10.1016/j.mce.2011.10.003
65. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 16(1):64-7. doi:10.1038/ng0597-64
66. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med (2009) 11(10):687-94. doi:10.1097/GIM.0b013e3181ac9aea
67. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control (2009) 16(1):8-13.
68. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst (2000) 92(11):924-30. doi:10.1093/jnci/92.11.924
69. Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control (2009) 16(1):38-45.
70. Ioffe YJ, Chiappinelli KB, Mutch DG, Zighelboim I, Goodfellow PJ. Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis? Gynecol Oncol (2012) 124(2):340-6. doi:10.1016/j.ygyno.2011.10.011
71. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Cancer Genome Atlas Research Network, et al. Integrated genomic characterization of endometrial carcinoma. Nature (2013) 497(7447):67-73. doi:10.1038/nature12113
72. Molife LR, Forster MD, Krebs M, Pwint T, Middleton MR, Kaye SB, et al. A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors (ASCO Meeting Abstracts). J Clin Oncol (2010) 28(15):2599. [Accessed 2013 Jun 7]. Available at: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/2599
73. Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol (2011) 8(5):302-6. doi:10.1038/nrclinonc.2011.42
74. Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 110(8):2916-21. doi:10.1073/pnas.1222577110
75. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin (2011) 61(2):69-90. doi:10.3322/caac.20107
76. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin (2012) 62(1):10-29. doi:10.3322/caac.21149
77. Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control (1997) 8(5):755-63. doi:10.1023/A:1018435522475
78. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 364(9447):1757-65. doi:10.1016/S0140-6736(04)17398-4
79. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 367(9518):1247-55. doi:10.1016/S0140-6736(06)68439-0
80. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 347(21):1645-51. doi:10.1056/NEJMoa020586
81. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 107(1):18-27. doi:10.1097/01.AOG.0000192397.41191.fb
82. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 6(5):271-8. doi:10.1016/S1470-2045(05)70101-7
83. Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, et al. Cervical cancer. J Natl Compr Canc Netw (2010) 8(12):1388-416.
84. Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res (2013) 73(7):2271-80. doi:10.1158/0008-5472.CAN-12-3000
85. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res (2005) 52(1):25-33. doi:10.1016/j.phrs.2005.02.010
86. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res (2000) 6(7):2860-7.
87. Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res (2003) 9(14):5370-9.
88. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst (2004) 96(1):56-67. doi:10.1093/jnci/djh005
89. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res (2004) 10(3):881-9. doi:10.1158/1078-0432.CCR-1144-3
90. Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo C, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther (2005) 4(9):1364-8. doi:10.1158/1535-7163.MCT-05-0128
91. Burkle A, Chen G, Kupper JH, Grube K, Zeller WJ. Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis (1993) 14(4):559-61. doi:10.1093/carcin/14.4.559
92. Smith LM, Willmore E, Austin CA, Curtin NJ. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res (2005) 11(23):8449-57. doi:10.1158/1078-0432.CCR-05-1224
93. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther (2003) 2(4):371-82.
94. Oza AM, Cibula D, Oaknin A, Poole CJ, Mathijssen RHJ, Sonke GS, et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study (ASCO Meeting Abstracts). J Clin Oncol (2012) 30(15):5001. [Accessed 2013 Jun 18]. Available at: http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001?sid=35889604-a227-482d-96ff-5d349c7e1856
95. Lee J, Annunziata CM, Minasian LM, Zujewski J, Prindiville SA, Kotz HL, et al. Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca) (ASCO Meeting Abstracts). J Clin Oncol (2011) 29(15):2520. [Accessed 2013 Jun 10]. Available at: http://meeting.ascopubs.org/cgi/content/short/29/15_suppl/2520?rss=1
96. Yu W, Gu K, Yu Z, Yuan D, He M, Ma N, et al. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. Cancer Lett (2013) 329(1):109-17. doi:10.1016/j.canlet.2012.10.024
97. Yadav A, Kumar B, Teknos TN, Kumar P. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther (2011) 10(7):1241-51. doi:10.1158/1535-7163.MCT-11-0004
98. Rajesh M, Mukhopadhyay P, Batkai S, Godlewski G, Hasko G, Liaudet L, et al. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem Biophys Res Commun (2006) 350(2):352-7. doi:10.1016/j.bbrc.2006.09.160
99. Pyriochou A, Olah G, Deitch EA, Szabo C, Papapetropoulos A. Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Int J Mol Med (2008) 22(1):113-8.
100. Tentori L, Lacal PM, Muzi A, Dorio AS, Leonetti C, Scarsella M, et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer (2007) 43(14):2124-33. doi:10.1016/j.ejca.2007.07.010
101. Liu J, Fleming GF, Tolaney SM, Birrer MJ, Penson RT, Berlin ST, et al. A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer (ASCO Meeting Abstracts). J Clin Oncol (2011) 29(15):5028. [Accessed 2013 Jun 10]. Available at: http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/5028?sid=a88c5b0a-3c23-4d7b-893a-877d2132a7db
102. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res (2003) 63(18):6008-15.
103. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A (1997) 94(14):7303-7. doi:10.1073/pnas.94.14.7303
104. Masutani M, Nozaki T, Nishiyama E, Shimokawa T, Tachi Y, Suzuki H, et al. Function of poly(ADP-ribose) polymerase in response to DNA damage: gene-disruption study in mice. Mol Cell Biochem (1999) 193(1-2):149-52. doi:10.1023/A:1006941016799
105. Veliparib with radiation therapy in patients with inflammatory or loco-regionally recurrent breast cancer. (2013). [Accessed 2013 June 18]. Available from: http://clinicaltrials.gov/ct2/show/NCT01477489?term=parp+inhibitors+and+radiation+and+breast+cancer&rank=1
106. Study of the poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor BSI-201 in patients with newly diagnosed malignant glioma. (2013). [Accessed 2013 Jun 18]. Available from: http://clinicaltrials.gov/ct2/show/NCT00687765?term=glioblastoma+multiforme+and+parp+inhibitors+and+radiation&rank=1
107. Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res (2010) 16(8):2344-51. doi:10.1158/1078-0432.CCR-09-2758
108. Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, et al. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. Cancer Res (2012) 72(22):5675-82. doi:10.1158/0008-5472.CAN-12-0324
109. Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, et al. Modeling pharmacodynamic response to the poly(ADP-ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. PLoS ONE (2011) 6(10):e26152. doi:10.1371/journal.pone.0026152
110. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res (2012) 18(6):1726-34. doi:10.1158/1078-0432.CCR-11-2821
111. Do K, Chen AP. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res (2013) 19(5):977-84. doi:10.1158/1078-0432.CCR-12-0163
112. Ang J, Yap TA, Fong P, Carden CP, Tan DS, Hanwell J, et al. Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC) (ASCO Meeting Abstracts). J Clin Oncol (2010) 28(15):5041. [Accessed 6/10/2013]. Available from: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5041
113. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 105(44):17079-84. doi:10.1073/pnas.0806092105
114. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer (2010) 10(4):293-301. doi:10.1038/nrc2812